CVR 26270367Private limited company (ApS)Ikke-finansielle holdingselskaber (642120)HellerupFounded 28 Sep 2001
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about NORDIC BIOTECH GENERAL PARTNER ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
163.7K
DKK, annual report 2025
+305.1% on 2024
Result
+178.2K
DKK, annual report 2025
Equity
1.2M
DKK, annual report 2025
TECH GROWTH INVEST ApSCVR 25146670, 66.7% to under 90% of capital and votes
C. HANSEN INVEST ApSCVR 26213118, 25% to under 33.3% of capital and votes
Group holding company
Dandex estimate: NACE 642120, controlled by a company; status is not activeFlorian Schønhartinguntil 23 Mar 2026
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 2514667066.7% to under 90% of capital and votesnotified 16 Dec 2025since 20 Jun 2002
CVR 2621311825% to under 33.3% of capital and votesnotified 15 Jun 2015since 20 Jun 2002
25% to under 33.3% of capital and votesnotified 15 Jun 201520 Jun 2002 to 16 Dec 2025
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 28 Sep 2001.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 163.7K, Result for the year 178.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 1.3M, Equity 1.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 16 | 12 | 8 | 40 | 164 |
| Result for the year | +8 | +4 | +35 | +67 | +178 |
| Equity | 930 | 934 | 969 | 1,036 | 1,214 |
| Total assets | 947 | 955 | 995 | 1,058 | 1,299 |
| Employees (average) | 0 | 0 | Not reported | Not reported | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | n.m.note 1 | -25.4% | -34.6% | 425.7% | 305.1% |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for NORDIC BIOTECH GENERAL PARTNER ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingNot read from the announcement | None | None | None | 125,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
16 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Likvidation vedtaget 23.03.2026
Likvidatorer:
Tiltrådte:
Jakob Mosegaard Larsen, 1256 København K, den 23.03.2026.
Direktion:
Fratrådte:
Florian Schønharting, den 23.03.2026.
Virksomheden tegnes af en likvidator
Virksomhedens kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Ny adresse: c/o NB Capital ApS, Strandvejen 125, 2900 Hellerup
CVR-nummer:
26270367.
NAVN:
NORDIC BIOTECH GENERAL PARTNER ApS.
Adresse: c/o NB Capital ApS, Østergade 24A, 1. tv., 1100 København K.
Kommune: København.
Vedtægter ændret: 29.05.2015
Vedtægter ændret:
09.01.2012.
Direktion:
Udtrådt af direktionen:
Christian Karsten Hansen, den 09.01.2012.
Ny adresse:
c/o NB Capital ApS, Østergade 24A, 1. tv., 1100 København K.
Vedtægter ændret:
23.08.2010.
Bestyrelse:
Udtrådt af bestyrelsen:
Florian Schønharting, den 23.08.2010, Christian Karsten Hansen, den 23.08.2010.
Direktion:
Indtrådt i direktionen:
Direktør Christian Karsten Hansen, den 23.08.2010, Direktør Florian Schønharting, den 23.08.2010.
Selskabet tegnes af den samlede direktion.
Vedtægter ændret:
31.01.2008.
Vedtægter ændret:
31.12.2004.
Bestyrelse:
Udtrådt af bestyrelsen:
Matthew Daniel Perry, den 31.12.2004.
Selskabet tegnes af den samlede bestyrelse.
Vedtægter ændret:
01.07.2004.
Bestyrelse:
Udtrådt af bestyrelsen:
Lars Grønborg Eskesen, den 20.06.2002, Claus Tycho Bræstrup, den 20.06.2002, Maja Kirstine Elsøe Engmark, den 20.06.2002.
Indtrådt i bestyrelsen:
Direktør Christian Karsten Hansen, den 20.06.2002, Direktør Florian Schønharting, den 20.06.2002.
Ny adresse:
Østergade 5, 3., 1100 København K.
Stiftelsesdato:
28.09.2001.
Seneste vedtægtsdato:
28.09.2001.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 100,00.
Stiftere:
CVR-NR. 56759913 H. LUNDBECK A/S, Ottiliavej 7-9, 2500 Valby, den 28.09.2001, CVR-NR. 25146670 TECH GROWTH INVEST ApS, c/o Lindh Stabell Horten A/S, Ved Stranden 18, postboks 2034, 1012 København K, den 28.09.2001, CVR-NR. 26213118 C. HANSEN INVEST ApS, Rungsted Strandvej 19, 2950 Vedbæk, den 28.09.2001, VækstFonden, den 28.09.2001, BVF/NexGen Investments, L.P, den 28.09.2001.
Bestyrelse:
Koncerndirektør Claus Tycho Bræstrup, den 28.09.2001, Direktør Lars Grønborg Eskesen, den 28.09.2001, Maja Kirstine Elsøe Nielsen, den 28.09.2001, Matthew Daniel Perry, den 28.09.2001.
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem.
Revision:
CVR-NR. 73317428 ERNST & YOUNG STATSAUTORISERET REVISIONSAKTIESELSKAB, Tagensvej 86, 2200 København N, den 28.09.2001.
Første regnskabsår:
28.09.2001 - 31.12.2002.
Regnskabsår:
01.01 - 31.12.
P-number 1008714254Strandvejen 125, 2900 Hellerup
P-number 1008712634Ved Stranden 18, 1012 København K